TY - JOUR
T1 - Meta-Analysis of Comparison Between Self-Expandable and Balloon-Expandable Valves for Patients Having Transcatheter Aortic Valve Implantation
AU - Moretti, Claudio
AU - D'Ascenzo, Fabrizio
AU - Mennuni, Marco
AU - Taha, Salma
AU - Brambilla, Nedy
AU - Nijhoff, Freek
AU - Fraccaro, Chiara
AU - Barbanti, Marco
AU - Tamburino, Corrado
AU - Tarantini, Giuseppe
AU - Rossi, Marco L.
AU - Presbitero, Patrizia
AU - Napodanno, Massimo
AU - Stella, Pieter
AU - Bedogni, Francesco
AU - Omedè, Pierluigi
AU - Conrotto, Federico
AU - Montefusco, Antonio
AU - Giordana, Francesca
AU - Biondi Zoccai, Giuseppe
AU - Agostoni, Piefrancesco
AU - D'Amico, Maurizio
AU - Rinaldi, Mauro
AU - Marra, Sebastiano
AU - Gaita, Fiorenzo
PY - 2015/6/15
Y1 - 2015/6/15
N2 - Two different devices, 1 self-expanding and 1 balloon-expandable, have been developed for patients who underwent transcatheter aortic valve implantation with contrasting data about efficacy and safety. Pubmed, Medline, and Google Scholar were systematically searched for studies of these different devices, with data derived from randomized controlled trial or registries with multivariate analysis. All-cause death at 30 days and at follow-up were the primary end points, whereas postprocedural moderate or severe aortic regurgitation (AR), stroke, major vascular complications, bleedings, and pacemaker implantation the secondary ones. Six studies with 957 self-expanding and 947 balloon-expandable valves were included: 1 randomized controlled trial and 5 observational studies. At 30 days follow-up, rates of death did not differ between self-expanding and balloon-expandable valves (odds ratio [OR] 0.74, 95% confidence interval [CI] 0.47 to 1.17), whereas balloon expandable reduced rates of moderate or severe AR (OR 0.51, 95% CI 0.27 to 0.99) and of pacemaker implantation (OR 0.28, 95% CI 0.17 to 0.47). After a follow-up of 360 days (300 to 390), rates of all-cause death did not differ between the 2 groups. In conclusion, risks of moderate or severe AR and pacemaker implantation were lower with the balloon-expandable devices without an impact on 30 days and midterm mortality.
AB - Two different devices, 1 self-expanding and 1 balloon-expandable, have been developed for patients who underwent transcatheter aortic valve implantation with contrasting data about efficacy and safety. Pubmed, Medline, and Google Scholar were systematically searched for studies of these different devices, with data derived from randomized controlled trial or registries with multivariate analysis. All-cause death at 30 days and at follow-up were the primary end points, whereas postprocedural moderate or severe aortic regurgitation (AR), stroke, major vascular complications, bleedings, and pacemaker implantation the secondary ones. Six studies with 957 self-expanding and 947 balloon-expandable valves were included: 1 randomized controlled trial and 5 observational studies. At 30 days follow-up, rates of death did not differ between self-expanding and balloon-expandable valves (odds ratio [OR] 0.74, 95% confidence interval [CI] 0.47 to 1.17), whereas balloon expandable reduced rates of moderate or severe AR (OR 0.51, 95% CI 0.27 to 0.99) and of pacemaker implantation (OR 0.28, 95% CI 0.17 to 0.47). After a follow-up of 360 days (300 to 390), rates of all-cause death did not differ between the 2 groups. In conclusion, risks of moderate or severe AR and pacemaker implantation were lower with the balloon-expandable devices without an impact on 30 days and midterm mortality.
UR - http://www.scopus.com/inward/record.url?scp=84930179130&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84930179130&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2015.03.015
DO - 10.1016/j.amjcard.2015.03.015
M3 - Article
C2 - 25890630
AN - SCOPUS:84930179130
VL - 115
SP - 1720
EP - 1725
JO - American Journal of Cardiology
JF - American Journal of Cardiology
SN - 0002-9149
IS - 12
M1 - 21053
ER -